MIL62, an injection therapy approved exclusively in China for neuromyelitis optica spectrum disorder (NMOSD), was found to keep most NMOSD patients free of relapses for up to two years, while being generally safe and well tolerated. That’s according to data from the Phase 1b portion of a single-center…
MIL62
Recent Posts
- Review shows approved treatment sharply cuts relapse risk in NMOSD
- Choosing courage and connection after the trauma of NMOSD
- NMOSD patients report lower sleep quality, study shows
- The bra line battle is a wardrobe crisis for women with NMOSD
- New antibody may explain mystery cases of NMOSD-like disease